Soluble Biomarkers – OMERACT

Skip to content

Home
- About Us
- Contact Us
Patient Research Partners
Future Leaders
- Fellows
- Emerging Leaders
Committees
Resources
Working Groups
- Initiating an OMERACT Working Group
Events
- OMERACT 2025

About the Soluble Biomarkers Working Group

The OMERACT Soluble Biomarkers Working Group is

Jasvinder-A-Singh-Final

Jasvinder A Singh

Co-Chair

VStrand linkedin_2278

Vibeke Strand

Co-Chair

Peter Tugwell

Peter Tugwell

Co-Chair

Working Group Publications

Definitions and Validation Criteria for Biomarkers and Surrogate Endpoints: Development and Testing of a Quantitative Hierarchical Levels of Evidence Schema

Testing of the Preliminary OMERACT Validation Criteria for a Biomarker to Be Regarded as Reflecting Structural Damage Endpoints in RA Clinical Trials: The Example of CRP

Development of Draft Validation Criteria for a Soluble Biomarker to Be Regarded as a Valid Biomarker Reflecting Structural Damage Endpoints in RA and SpA Clinical Trials

Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in RA: A Systematic Literature Search on 5 Candidate Biomarkers

Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in RA, PsA, and Spondyloarthritis: The OMERACT 9 v2 Criteria

Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in RA, PsA, and AS, and Recommendations for Study Design

Home
- About Us
- Contact Us
Patient Research Partners
Future Leaders
- Fellows
- Emerging Leaders
Committees
Resources
Working Groups
- Initiating an OMERACT Working Group
Events
- OMERACT 2025

Copyright © 2024 OMERACT | Powered by Astra WordPress Theme

Scroll to Top